Control of group C meningococcal disease in Australian aboriginal children by mass rifampicin chemoprophylaxis and vaccination.
An outbreak of 12 cases of meningitis, 11 caused by Neisseria meningitidis serogroup C, occurred at Doomadgee from September, 1990, to April, 1991. The incidence of meningitis was 17.55/10(3) person-years. Only children aged 1-10 years were affected. In October, 1990, or shortly thereafter, 473/509 children aged between 1 and 15 years inclusive had one dose of Mencevax AC. From the time of vaccination until April, 1991, a further eight cases occurred, six in vaccinated children. Vaccine efficacy in 1-15 year olds was calculated as 77%. Despite this, in April, 1991, the prevalence of antibody to group C polysaccharide in vaccinated children (78%) was not significantly different from that in unvaccinated children and adults. 46 nonresponders were revaccinated, and, in February, 1992, 78% had antibodies to group C polysaccharide. In April, 1991, an estimated 3.0% of the population had group C organisms, carriage being directly related to household crowding. In June, 1991, 2 months after mass prophylaxis with rifampicin, none of these individuals were carriers. In October, 1991, the carriage rate of group C organisms was 0.64%. There have been no further cases caused by the epidemic strain. Although uncrowded housing is a basic need, mass chemoprophylaxis and two doses of vaccine for children should be used in similar outbreaks.
Pearce
M C
MC
Communicable Diseases Branch, Queensland Health, Brisbane, Australia.
Sheridan
J W
JW
Jones
D M
DM
Lawrence
G W
GW
Murphy
D M
DM
Masutti
B
B
McCosker
C
C
Douglas
V
V
George
D
D
O'Keefe
A
A
D000293:Adolescent; D001315:Australia / Q000453:epidemiology; D001428:Bacterial Vaccines / Q000627:therapeutic use*; D002353:Carrier State / Q000208:ethnology / Q000517:prevention & control; D002648:Child; D002675:Child, Preschool; D004196:Disease Outbreaks / Q000517:prevention & control / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D007117:Immunization, Secondary; D015994:Incidence; D007223:Infant; D008297:Male; D008585:Meningitis, Meningococcal / Q000208:ethnology / Q000517:prevention & control*; D022401:Meningococcal Vaccines; D009345:Neisseria meningitidis / Q000276:immunology*; D011135:Polysaccharides, Bacterial / Q000627:therapeutic use*; D012293:Rifampin / Q000627:therapeutic use*
D001428:Bacterial Vaccines; C094429:Mencevax AC; D022401:Meningococcal Vaccines; D011135:Polysaccharides, Bacterial; D012293:Rifampin